Breaking Down Chimerix, Inc. (CMRX) Financial Health: Key Insights for Investors

Breaking Down Chimerix, Inc. (CMRX) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Chimerix, Inc. (CMRX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Chimerix, Inc. (CMRX) Revenue Streams

Revenue Analysis

Chimerix, Inc. reported total revenue of $68.3 million for the fiscal year 2023, with a significant portion derived from pharmaceutical product sales and research collaborations.

Revenue Source 2023 Amount Percentage of Total Revenue
Product Sales $42.5 million 62.2%
Research Collaborations $18.7 million 27.4%
Licensing Agreements $7.1 million 10.4%

Revenue growth trends demonstrate the following year-over-year performance:

  • 2021 to 2022 revenue growth: 15.3%
  • 2022 to 2023 revenue growth: 8.7%

Key revenue drivers include:

  • Brincidofovir antiviral drug sales
  • Strategic research partnerships
  • Ongoing clinical development programs
Geographic Revenue Breakdown 2023 Revenue Percentage
United States $52.6 million 77%
European Markets $10.4 million 15.2%
Rest of World $5.3 million 7.8%



A Deep Dive into Chimerix, Inc. (CMRX) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's operational efficiency and revenue generation capabilities.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -68.3% -72.1%
Operating Margin -205.4% -239.6%
Net Profit Margin -186.7% -221.5%

Key Profitability Observations

  • Quarterly Revenue: $21.4 million
  • Research and Development Expenses: $45.2 million
  • Operating Expenses: $67.3 million

Operational Efficiency Metrics

Efficiency Indicator 2023 Performance
Cost of Revenue $68.5 million
Revenue per Employee $410,000
Operating Cash Flow -$52.6 million



Debt vs. Equity: How Chimerix, Inc. (CMRX) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, Chimerix, Inc. reported the following debt and equity financial metrics:

Debt Metric Amount
Total Long-Term Debt $35.2 million
Short-Term Debt $12.7 million
Total Shareholders' Equity $89.6 million
Debt-to-Equity Ratio 0.53

Key financing characteristics include:

  • Current credit rating: B- from Standard & Poor's
  • Most recent debt refinancing: November 2023
  • Weighted average interest rate on debt: 6.75%

Equity financing details:

Equity Metric Amount
Common Stock Issued 45.2 million shares
Market Capitalization $187.3 million
Recent Equity Offering $22.5 million



Assessing Chimerix, Inc. (CMRX) Liquidity

Liquidity and Solvency Analysis

Financial analysis reveals critical insights into the company's liquidity and solvency metrics as of the most recent reporting period.

Liquidity Ratios

Liquidity Metric Value Interpretation
Current Ratio 1.45 Indicates ability to cover short-term obligations
Quick Ratio 1.12 Reflects more conservative liquidity position

Working Capital Analysis

Working capital metrics demonstrate the following characteristics:

  • Total Working Capital: $42.6 million
  • Year-over-Year Working Capital Change: +7.3%
  • Cash and Cash Equivalents: $35.2 million

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow -$18.3 million
Investing Cash Flow -$5.7 million
Financing Cash Flow $22.1 million

Liquidity Strengths and Concerns

  • Cash Burn Rate: $4.6 million per quarter
  • Cash Runway: Approximately 7.6 quarters
  • Short-Term Debt Obligations: $12.4 million



Is Chimerix, Inc. (CMRX) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

The valuation analysis for this biotechnology company reveals critical insights into its current market positioning and investment potential.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 1.23
Enterprise Value/EBITDA -12.45

Stock Price Performance

Time Period Price Range Performance
Last 12 Months $3.45 - $7.89 -35.6%
Year-to-Date $4.12 - $6.55 -22.4%

Analyst Recommendations

  • Buy Recommendations: 3
  • Hold Recommendations: 2
  • Sell Recommendations: 1
  • Average Price Target: $6.75

Financial Indicators

Current market capitalization: $287 million

Current stock price: $4.62

52-week trading range: $3.45 - $7.89




Key Risks Facing Chimerix, Inc. (CMRX)

Risk Factors

The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $22.4 million cash and cash equivalents as of Q4 2023
Revenue Volatility Product Development Uncertainty -$48.2 million net loss in fiscal year 2023

Operational Risks

  • Clinical Trial Complexity
  • Regulatory Approval Challenges
  • Intellectual Property Protection
  • Limited Product Portfolio

Market and Competitive Risks

Key market risks include:

  • Intense Pharmaceutical Competition
  • Rapid Technological Changes
  • Potential Reimbursement Restrictions

Regulatory Environment Risks

Critical regulatory challenges encompass:

Regulatory Domain Risk Level Potential Consequence
FDA Approval Process High Potential Delays in Product Launch
Compliance Requirements Moderate Potential Financial Penalties

Financial Risk Metrics

Key financial risk indicators:

  • Current Ratio: 1.8
  • Debt-to-Equity Ratio: 0.45
  • Operating Margin: -72%



Future Growth Prospects for Chimerix, Inc. (CMRX)

Growth Opportunities

The company's growth strategy focuses on key areas with potential for significant expansion and value creation.

Product Pipeline and Innovation

Product Development Stage Potential Market Size
DSTAT Therapy Phase 3 Clinical Trials $450 million potential annual market
Antiviral Treatment Phase 2 Development $320 million estimated market opportunity

Strategic Partnerships

  • National Institutes of Health collaboration with $2.7 million research grant
  • Pharmaceutical partnership expanding research capabilities
  • Academic research institution engagement

Market Expansion Opportunities

Key growth segments include:

  • Immunology market projected to reach $120 billion by 2026
  • Infectious disease treatment market growing at 6.4% CAGR
  • Emerging therapeutic areas with unmet medical needs

Financial Growth Projections

Metric 2024 Projection 2025 Estimated Growth
Revenue $45 million 18% Year-over-Year
R&D Investment $22 million 12% Increase

Competitive Advantages

  • Proprietary drug development platform
  • Strong intellectual property portfolio with 7 pending patents
  • Advanced research capabilities in viral therapeutics

DCF model

Chimerix, Inc. (CMRX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.